Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Increased Thromboinflammation Is Associated with High Thrombotic Risk in Patients with Myeloproliferative Neoplasms: A Multicentric Study of 394 Cases By the French Intergroup of Myeloproliferative Neoplasms (FIM)

Blood (2024) 144 (Supplement 1): 3133.

https://doi.org/10.1182/blood-2024-194702

Published: 2024

Journal Articles

Outcome of Patients with Accelerated and Blast-Phase Myeloproliferative Neoplasms Ineligible for Intensive Chemotherapy or Allogeneic Hematopoietic Cell Transplantation Treated By Azacitidine Alone or in Combination - a FIM Study

Blood (2024) 144 (Supplement 1): 3167.

https://doi.org/10.1182/blood-2024-199055

Published: 2024

Journal Articles

Phase 1/2 Study of the Activin Receptor-like Kinase-2 Inhibitor Zilurgisertib (INCB000928, LIMBER-104) As Monotherapy or with Ruxolitinib in Patients with Anemia Due to Myelofibrosis

Blood (2023) 142 (Supplement 1): 624.

https://doi.org/10.1182/blood-2023-179291

Published: 2023

Journal Articles

Impact of the COVID-19 Epidemic on Patients with Myeloproliferative Neoplasia: The French Prospective Observational Study Covim

Blood (2022) 140 (Supplement 1): 6847–6849.

https://doi.org/10.1182/blood-2022-156632

Published: 2022

Journal Articles

Final Results of Ruxopeg, a Phase 1/2 Adaptive Randomized Trial of Ruxolitinib (Rux) and Pegylated Interferon Alpha (IFNa) 2a in Patients with Myelofibrosis (MF)

Jean-Jacques Kiladjian, Jean-Christophe Ianotto, Juliette Soret, Nabih Maslah, Cendrine Chaffaut, Françoise Boyer perrard, Fiorenza Barraco, Viviane Dubruille, Claude Capron, Amandine Tisserand, Valérie Rolland-Neyret, Zineb Ghrieb, Sylvie Chevret, Isabelle Plo, Marie-Hélène Schlageter, Veronique Meignin, Matthieu Resche-Rigon, Bruno Cassinat

Blood (2022) 140 (Supplement 1): 577–578.

https://doi.org/10.1182/blood-2022-156389

Published: 2022

Journal Articles

In silico and Functional Studies for Classification of EPAS1/HIF2A Genetic Variants Identified in Patients with Erythrocytosis

Valéna Karaghiannis, Darko Maric, Céline Garrec, Nada Maaziz, Alexandre Buffet, Vincent Antunes, Amandine le Roy, Fabrice Airaud, Bernard Aral, Loic Schmitt, Sébastien Corbineau, Lamisse Mansour-Hendili, Valentine Lesieur, Antoine Rimbert, Fabien Laporte, Marine Delamare, Stephane Bezieau, Bruno Cassinat, Frédéric Galactéros, Anne-Paule Gimenez-Roqueplo, Nelly Burnichon, Holger Cario, Richard van Wijk, Celeste Bento, Anaise Blouet, Juliette Bouteloup, Françoise Boyer perrard, Aisha Aiko Bruce, Emilie Cayssials, Nicole Casadevall, Brieuc Cherel, Marielaure Couec, Louis Drevon, Cecile Dumesnil, Thierry Lamy De La Chapelle, Marion Gambart, Loic Garcon, Brigitte Granel, Pierre Hirsch, Agnès Lahary, Amira Mejri, Sandrine Meunier, Franck E. Nicolini, Emmanuel Raffoux, Dana Ranta, Nicolas Schleinitz, Jean Baptiste Valentin, Mathieu Wemeau, Francois Girodon, David Hoogewijs, Betty Gardie, Olivier Hermine

Blood (2022) 140 (Supplement 1): 8157–8158.

https://doi.org/10.1182/blood-2022-163123

Published: 2022

Journal Articles

Thrombosis with Non-Proliferative Complete Blood Count Indicative of Underlying Myeloproliferative Neoplasm, Sythrom, a Study on Behalf of the FIM Group

Blood (2022) 140 (Supplement 1): 9668–9669.

https://doi.org/10.1182/blood-2022-159928

Published: 2022

Journal Articles

Prospective Follow-up of Patients with Myelofibrosis (MF) and Treated with Ruxolitinib in France: The Rumycup Study

Jean-Jacques Kiladjian, Françoise Boyer perrard, Kamel Laribi, Jean-Christophe Ianotto, Dana Ranta, Omar Benbrahim, Serge Bologna, Pascale Cony-Makhoul, Alberto Santagostino, Hacene Zerazhi, Abla Slimani, Olivier Fitoussi, Gabriel Etienne

Blood (2022) 140 (Supplement 1): 3968–3969.

https://doi.org/10.1182/blood-2022-156628

Published: 2022

Journal Articles

Characteristics of High-Risk Polycythemia Vera Patients with Suboptimal Response to First-Line Therapy Who Switched to Ruxolitinib Vs Those Who Did Not Switch: Findings from PV-Switch, a Multinational, Retrospective Chart Review Study

Steffen Koschmieder, Clemens Schulte, Eyck von der Heyde, Lambert Busque, Françoise Boyer-Perrard, Timothy Devos, Francesco Passamonti, Mike W. Zuurman, Carole Paley, Geralyn Gilotti, Wendy Y. Cheng, Chi Gao, Mu Cheng, Melody Wu, Mei Sheng Duh, Claire N. Harrison

Blood (2021) 138 (Supplement 1): 3646.

https://doi.org/10.1182/blood-2021-148254

Published: 2021

Journal Articles

The Final Analysis of Expand: A Phase 1b, Open-Label, Dose-Finding Study of Ruxolitinib (RUX) in Patients (pts) with Myelofibrosis (MF) and Low Platelet (PLT) Count (50 × 10 9 /L to < 100 × 10 9 /L) at Baseline

Paola Guglielmelli, MD, Jean-Jacques Kiladjian, MD PhD, Alessandro M. Vannucchi, MD, Ming-hui Duan, MD, Haitao Meng, MD PhD, Ling Pan, MD PhD, Guangsheng He, MD PhD, Srdan Verstovsek, MD PhD, Françoise Boyer-Perrard, MD, Fiorenza Barraco, MD, Dietger Niederwieser, MD PhD, Anna Marina Liberati, MD, Claire Harrison, DM, FRCP, FRCPath, Pantelia Roussou, MSc, Monika Wroclawska, MD, Kevin Majidi, Peter AW te Boekhorst, MD PhD, Heinz Gisslinger, MD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-137742

Published: 2020

Journal Articles

Ruxopeg, a Multi-Center Bayesian Phase 1/2 Adaptive Randomized Trial of the Combination of Ruxolitinib and Pegylated Interferon Alpha 2a in Patients with Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis

Jean-Jacques Kiladjian, MD PhD, Juliette Soret-Dulphy, MD, Matthieu Resche-Rigon, MD PhD, Francoise Boyer-Perrard, MD, Fiorenza Barraco, MD, Valérie Rolland-Neyret, Claude Capron, Sylvie Chevret, MD PhD, Stephane Giraudier, MD PhD, Bruno Cassinat, PharmD, PhD

Blood (2018) 132 (Supplement 1): 581.

https://doi.org/10.1182/blood-2018-99-110785

Published: 2018

Journal Articles

Long Term Outcome of Patients with MPN-Associated Myelofibrosis Treated with Peg-Interferon-α2a, a French Intergroup of Myeloproliferative Neoplasms (FIM) Study

Blood (2017) 130 (Supplement 1): 323.

https://doi.org/10.1182/blood.V130.Suppl_1.323.323

Published: 2017

Journal Articles

Symptom Burden As Primary Driver for Therapy in Patients with Myelofibrosis: An Analysis By MPN International Quality of Life Study Group

Robyn M. Scherber, MD MPH, Holly Geyer, MD, Amylou Constance Dueck, PhD, Heidi E. Kosiorek, MS, Jean-Jacques Kiladjian, MD PhD, Stefanie Slot, Sonja Zweegman, MD PhD, Peter Te Boekhorst, Suzan Commandeur, MSc, Harry C. Schouten, Federico Sackmann, MD, Ana Kerguelen Fuentes, MD, Dolores Hernandez-Maraver, PhD, Heike L Pahl, PhD, Martin Griesshammer, MD, Frank Stegelmann, MD, Konstanze Doehner, MD, Thomas Lehmann, Karen Bonatz, Andreas Reiter, MD, Francoise Boyer, MD, Gabriel Etienne, MD PhD, Jean Christophe Ianotto, Dana Ranta, MD, Lydia Roy, MD, Jean-Yves Cahn, MD, Claire N. Harrison, DM, FRCP, FRCPath, Deepti Radia, MBBS, MRCPI, FRCPath MSc, MD, Pablo J. Muxi, MD, Norman I Maldonado, MD, Carlos Besses, MD PhD, Francisco Cervantes, MD PhD, Peter L. Johansson, MD PhD, Tiziano Barbui, MD, Giovanni Barosi, Alessandro M. Vannucchi, MD, Bjorn Andreasson, Maria Ferarri, Alessandro Rambaldi, MD, Jan Samuelsson, MD PhD, Gunnar Birgegard, MD PhD, Keith Cannon, MD, Xuijuan Sun, Junqing Xu, Peihong Zhang, Zefeng Xu, Ruben A. Mesa, MD

Blood (2016) 128 (22): 3117.

https://doi.org/10.1182/blood.V128.22.3117.3117

Published: 2016

Journal Articles

Efficacy and Safety of Erythropoietic-Stimulating Agents with Ruxolitinib in Myelofibrosis Patients : A Retrospective Analysis on 45 Patients. on Behalf of the French Intergroup of Myeloproliferative Disorders (FIM)

Sandra Malak, MD, Pascale Cony-Makhoul, MD, Jean-Christophe Ianotto, MD, Dana Ranta, MD, Philippe Rodon, MD, Fabienne Vacheret, MD, Barraco Fiorenza, MD, Francoise Boyer, MD, Katell Le Du, MD, Loic Garcon, MD PhD, Francois Lefrere, MD, Mathieu Wemeau, MD, Valerie Ugo, MD PhD, Jean-Jacques Kiladjian, MD PhD, Lydia Roy, MD

Blood (2016) 128 (22): 3123.

https://doi.org/10.1182/blood.V128.22.3123.3123

Published: 2016

Journal Articles

Myelofibrosis in Real Life: Findings from the French Intergroup of Myeloproliferative Neoplasms (FIM) Registry

Blood (2016) 128 (22): 3128.

https://doi.org/10.1182/blood.V128.22.3128.3128

Published: 2016

Journal Articles

Consideration of Symptom Burden Based Treatment in PV and ET Patients: An Analysis By MPN International Quality of Life Study Group

Robyn M. Scherber, MD MPH, Holly Geyer, MD, Heidi E. Kosiorek, MS, Amylou C. Dueck, PhD, Jean-Jacques Kiladjian, MD PhD, Stefanie Slot, Sonja Zweegman, MD PhD, Peter Te Boekhorst, Suzan Commandeur, MSc, Harry C. Schouten, Federico Sackmann, MD, Ana Kerguelen Fuentes, Dolores Hernandez-Maraver, PhD, Heike L Pahl, PhD, Martin Griesshammer, MD, Frank Stegelmann, MD, Konstanze Doehner, MD, Thomas Lehmann, Karen Bonatz, Andreas Reiter, MD, Francoise Boyer, MD, Gabriel Etienne, MD PhD, Jean Christophe Ianotto, Dana Ranta, MD, Lydia Roy, MD, Jean-Yves Cahn, MD, Claire N. Harrison, DM, FRCP, FRCPath, Deepti Radia, MBBS, MRCPI, FRCPath MSc, MD, Pablo J. Muxi, MD, Norman I Maldonado, MD, Carlos Besses, MD PhD, Francisco Cervantes, MD PhD, Peter L. Johansson, MD PhD, Tiziano Barbui, MD, Giovanni Barosi, Alessandro M. Vannucchi, MD, Francesco Passamonti, MD, Bjorn Andreasson, Maria Ferrari, Alessandro Rambaldi, MD, Jan Samuelsson, MD PhD, Keith Cannon, MD, Xiujuan Sun, MD, Junqing Xu, Peihong Zhang, Zefeng Xu, Ruben A. Mesa, MD

Blood (2016) 128 (22): 5463.

https://doi.org/10.1182/blood.V128.22.5463.5463

Published: 2016

Journal Articles

Sequential Analysis By Next Generation Sequencing of 18 Genes in Polycythemia Vera and Essential Thrombocythemia Reveals a Association Between Mutational Status and Clinical Outcome after 3-Year Follow-up

Damien Luque Paz, MD, Aurelie Chauveau, MD, Caroline Buors, MD, Jean-Christophe Ianotto, MD, Francoise Boyer, MD, Laura Samaison, MD, Claude Ferec, MD PhD, Cedric Le Marechal, MD PhD, Paul Gueguen, MD, Valerie Ugo, MD PhD

Blood (2015) 126 (23): 2808.

https://doi.org/10.1182/blood.V126.23.2808.2808

Published: 2015

Journal Articles

EXPAND: A Phase 1b, Open-Label, Dose-Finding Study of Ruxolitinib in Patients with Myelofibrosis (MF) and Low Platelet Counts (50 × 10 9 /L to 99 × 10 9 /L) at Baseline

Alessandro M. Vannucchi, MD, Heinz Gisslinger, MD, Claire N. Harrison, Haifa Kathrin Al-Ali, MD, Ester Pungolino, MD, Jean-Jacques Kiladjian, MD PhD, Francoise Boyer-Perrard, MD, Franck E. Nicolini, MD PhD, Shuyuan Mo, Edric Atienza, MSHS, Prashanth Gopalakrishna, MBBS, MRCS, Peter A. te Boekhorst

Blood (2015) 126 (23): 2817.

https://doi.org/10.1182/blood.V126.23.2817.2817

Published: 2015

Journal Articles

Impact of Disease Duration upon Symptom Burden Amongst Patients with Myeloproliferative Neoplasms (MPNs)

Robyn M. Scherber, MD MPH, Holly Geyer, MD, Claire N. Harrison, Heidi E. Kosiorek, MS, Amylou C. Dueck, PhD, Jean-Jacques Kiladjian, MD PhD, Stefanie Slot, Zhijian Xiao, DO, Sonja Zweegman, MD PhD, Federico Sackmann, Ana Kerguelen Fuentes, Dolores Hernandez-Maraver, PhD, Konstanze Döhner, MD, Deepti Radia, Pablo J. Muxi, MD, Carlos Besses, Francisco Cervantes, MD PhD, Peter L. Johansson, MD PhD, Bjorn Andreasson, MDPhD, Alessandro Rambaldi, MD, Tiziano Barbui, MD, Karin Bonatz, Andreas Reiter, MD, Francoise Boyer, MD, Gabriel Etienne, MD PhD, Jean-Christophe Ianotto, Dana Ranta, Jean Roy, MD, Jean-Yves Cahn, Norman I Maldonado, MD, Giovanni Barosi, MD, Maria Ferrari, Robert Peter Gale, MD PhD DSc, Gunnar Birgegard, MD PhD, Zefeng Xu, MD, Yu Zhang, B.S., Xiujuan Sun, MD, Junqing Xu, Peihong Zhang, Peter A. te Boekhorst, Suzan Commandeur, Harry C. Schouten, MD PhD, Heike L Pahl, PhD, Martin Griesshammer, MD, Frank Stegelmann, MD, Thomas Lehmann, Alessandro M. Vannucchi, MD, Francesco Passamonti, MD, Jan Samuelsson, MD PhD, Ruben A. Mesa, MD

Blood (2015) 126 (23): 4073.

https://doi.org/10.1182/blood.V126.23.4073.4073

Published: 2015

Journal Articles

Symptom Burden Profile in Myelofibrosis Patients with Thrombocytopenia: Lessons and Unmet Needs

Holly Geyer, MD, Robyn M Scherber, MD MPH, Heidi Kosiorek, Amylou C. Dueck, PhD, Jean-Jacques Kiladjian, MD PhD, Zhijian Xiao, MD, Stefanie Slot, Sonja Zweegman, MD PhD, Federico Sackmann, Ana Kerguelen Fuentes, Dolores Hernandez-Maraver, PhD, Konstanze Dohner, MD, Claire N. Harrison, Deepti Radia, Pablo J. Muxi, MD, Carlos Besses, Francisco Cervantes, Peter L. Johansson, MD PhD, Bjorn Andreasson, MDPhD, Alessandro Rambaldi, MD, Tiziano Barbui, MD, Karin Bonatz, Andreas Reiter, MD, Francoise Boyer, MD, Gabriel Etienne, MD PhD, Jean-Christophe Ianotto, MD, Dana Ranta, Lydia Roy, MD, Jean-Yves Cahn, Norman I Maldonado, MD, Giovanni Barosi, Maria Ferrari, Robert Peter Gale, MD PhD DSc, Gunnar Birgegard, MD PhD, Zefeng Xu, MD, Yue Zhang, MD, Xiujuan Sun, MD, Junqing Xu, Peihong Zhang, Peter te Boekhorst, Suzan Commandeur, Harry C. Schouten, MD PhD, Heike L Pahl, PhD, Martin Griesshammer, MD, Frank Stegelmann, MD, Thomas Lehmann, Alessandro M. Vannucchi, Francesco Passamonti, MD, Jan Samuelsson, MD PhD, Ruben A. Mesa, MD

Blood (2015) 126 (23): 4080.

https://doi.org/10.1182/blood.V126.23.4080.4080

Published: 2015

NARROW

Increased Thromboinflammation Is Associated with High Thrombotic Risk in Patients with Myeloproliferative Neoplasms: A Multicentric Study of 394 Cases By the French Intergroup of Myeloproliferative Neoplasms (FIM)

Outcome of Patients with Accelerated and Blast-Phase Myeloproliferative Neoplasms Ineligible for Intensive Chemotherapy or Allogeneic Hematopoietic Cell Transplantation Treated By Azacitidine Alone or in Combination - a FIM Study

Phase 1/2 Study of the Activin Receptor-like Kinase-2 Inhibitor Zilurgisertib (INCB000928, LIMBER-104) As Monotherapy or with Ruxolitinib in Patients with Anemia Due to Myelofibrosis

Impact of the COVID-19 Epidemic on Patients with Myeloproliferative Neoplasia: The French Prospective Observational Study Covim

Final Results of Ruxopeg, a Phase 1/2 Adaptive Randomized Trial of Ruxolitinib (Rux) and Pegylated Interferon Alpha (IFNa) 2a in Patients with Myelofibrosis (MF)

In silico and Functional Studies for Classification of EPAS1/HIF2A Genetic Variants Identified in Patients with Erythrocytosis

Thrombosis with Non-Proliferative Complete Blood Count Indicative of Underlying Myeloproliferative Neoplasm, Sythrom, a Study on Behalf of the FIM Group

Prospective Follow-up of Patients with Myelofibrosis (MF) and Treated with Ruxolitinib in France: The Rumycup Study

Characteristics of High-Risk Polycythemia Vera Patients with Suboptimal Response to First-Line Therapy Who Switched to Ruxolitinib Vs Those Who Did Not Switch: Findings from PV-Switch, a Multinational, Retrospective Chart Review Study

The Final Analysis of Expand: A Phase 1b, Open-Label, Dose-Finding Study of Ruxolitinib (RUX) in Patients (pts) with Myelofibrosis (MF) and Low Platelet (PLT) Count (50 × 10 9 /L to < 100 × 10 9 /L) at Baseline

Ruxopeg, a Multi-Center Bayesian Phase 1/2 Adaptive Randomized Trial of the Combination of Ruxolitinib and Pegylated Interferon Alpha 2a in Patients with Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis

Long Term Outcome of Patients with MPN-Associated Myelofibrosis Treated with Peg-Interferon-α2a, a French Intergroup of Myeloproliferative Neoplasms (FIM) Study

Symptom Burden As Primary Driver for Therapy in Patients with Myelofibrosis: An Analysis By MPN International Quality of Life Study Group

Efficacy and Safety of Erythropoietic-Stimulating Agents with Ruxolitinib in Myelofibrosis Patients : A Retrospective Analysis on 45 Patients. on Behalf of the French Intergroup of Myeloproliferative Disorders (FIM)

Myelofibrosis in Real Life: Findings from the French Intergroup of Myeloproliferative Neoplasms (FIM) Registry

Consideration of Symptom Burden Based Treatment in PV and ET Patients: An Analysis By MPN International Quality of Life Study Group

Sequential Analysis By Next Generation Sequencing of 18 Genes in Polycythemia Vera and Essential Thrombocythemia Reveals a Association Between Mutational Status and Clinical Outcome after 3-Year Follow-up

EXPAND: A Phase 1b, Open-Label, Dose-Finding Study of Ruxolitinib in Patients with Myelofibrosis (MF) and Low Platelet Counts (50 × 10 9 /L to 99 × 10 9 /L) at Baseline

Impact of Disease Duration upon Symptom Burden Amongst Patients with Myeloproliferative Neoplasms (MPNs)

Symptom Burden Profile in Myelofibrosis Patients with Thrombocytopenia: Lessons and Unmet Needs

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only